Autoimmune myocarditis

Article written and reviewed by Dr Luca Moretti

Autoimmune myocarditis is inflammation of the myocardium sustained by an adaptive response against self cardiac antigens. It may present as an organ-specific disease, persist after a possible infectious trigger, or accompany lupus, systemic sclerosis, inflammatory myopathies, vasculitides and other systemic conditions. The definition requires positive evidence of inflammation and immunologic coherence, not simply the absence of an identified agent.

The boundary with inflammatory cardiomyopathy is temporal and conceptual; myocarditis describes the inflammatory process, whereas cardiomyopathy emphasizes persistent dysfunction and remodeling. An autoimmune episode may heal without sequelae or maintain necrosis, autoantigen exposure and fibrosis until a chronic dilated phenotype develops.

Not every cardiac manifestation of an autoimmune disease is myocarditis; pericarditis, ischemia due to accelerated atherosclerosis or vasculitis, microangiopathy, pulmonary hypertension, valvular disease, thrombosis and treatment toxicity can elevate biomarkers and reduce function. Defining the mechanism is essential because anticoagulation, revascularization and immunosuppression address different problems.

Immunosuppression is potentially effective when immunity is the driver of injury, but it increases the risk of infections and reactivations; a diagnosis based only on CMR or autoantibodies does not automatically justify corticosteroids. In severe presentations, endomyocardial biopsy and molecular testing for infectious agents can provide the strongest basis for a high-impact decision.

Management integrates cardiology, rheumatology or clinical immunology, infectious diseases and pathology; the goal is not merely to normalize troponin, but to control systemic activity, protect function and prevent arrhythmias and scarring. The plan is adapted to histologic subtype, organs involved, fertility, comorbidities and previous therapies.

Etiology, Pathogenesis and Pathophysiology

Loss of tolerance allows expansion of autoreactive T lymphocytes and production of autoantibodies against cardiomyocyte proteins, receptors and intracellular structures. Initial injury releases additional antigens and broadens the response through epitope spreading; cytokines, complement and cytotoxic cells alter contractility, conduction and cell survival.

Molecular mimicry provides a possible link between infection and autoimmunity: microbial epitopes similar to cardiac components may activate cross-reactive clones. This does not mean that every post-infectious myocarditis is autoimmune or that the virus has certainly disappeared; in an individual patient, microbial persistence and autoimmunity may coexist and require tissue characterization.

In lupus, immune complexes, complement, vasculopathy and autoantibodies contribute to injury, often together with pericarditis; clinical myocarditis is less frequent than subclinical involvement reported by imaging or autopsy. Disease activity, complement consumption and involvement of other organs support the context, but do not replace exclusion of coronary disease and infection.

In systemic sclerosis, microvasculopathy, repeated ischemia, inflammation and interstitial fibrosis can produce dysfunction and arrhythmias. The phenotype does not always correspond to classic acute myocarditis and CMR may distinguish active edema from fibrosis; pulmonary hypertension and right-sided involvement must be assessed separately.

Dermatomyositis, polymyositis and antisynthetase syndromes may involve the myocardium and conduction system. Troponin T may rise because of expression in regenerating skeletal muscle, whereas troponin I has greater cardiac specificity in the setting of myopathies; weakness, dysphagia and interstitial lung disease affect symptoms and prognosis beyond ventricular function.

ANCA-associated vasculitides and EGPA may cause myocarditis, coronary arteritis, ischemia and eosinophilic infiltration; in EGPA, eosinophils, granulomas and vasculitis overlap in different proportions. The page on eosinophilic myocarditis describes the histologic subtype, whereas the systemic diagnosis determines induction and maintenance.

Genetic predisposition modulates vulnerability because variants in desmosomal or cytoskeletal genes may manifest after inflammatory stress and mimic recurrent myocarditis. Autoimmunity and inherited cardiomyopathy are not mandatory alternatives; family investigation is appropriate in recurrences, disproportionate arrhythmias or a persistent phenotype.

Anti-heart autoantibodies have been described in myocarditis and dilated cardiomyopathy and may occur in relatives, but techniques and antigens are not uniform. Some antibodies have experimental functional activity, whereas others are markers of injury; their clinical use remains specialized and does not replace biopsy, imaging or phenotypic assessment.

Transition to chronic disease depends on failure to resolve the infiltrate, cell death, fibroblast activation and neurohormonal remodeling. Once dilation is established, immune control must be accompanied by complete heart-failure therapy; persistence of inflammation and the amount of scar are different dimensions of the same disease.

Humoral immunity can alter the heart even without a dense cellular infiltrate. Functional antibodies against adrenergic or muscarinic receptors have been studied in cardiomyopathy, but their causal role and test availability remain limited. Procedures such as immunoadsorption are not a generally applicable standard therapy and are considered only within protocols or experienced centers.

Autoimmune vascular injury alters perfusion at multiple levels; epicardial vasculitis, microangiopathy, coronary Raynaud phenomenon and antiphospholipid-antibody thrombosis may cause necrosis that fuels further autoimmunity. The distinction between vascular and interstitial disease is not academic because it guides antiplatelet therapy, anticoagulation, vasodilation and the intensity of immunosuppression.

Clinical Manifestations

The acute presentation includes chest pain, dyspnea, palpitations, syncope and fever, with an infarct-like syndrome or heart failure; a fulminant form may cause shock and arrhythmias within days. At the opposite extreme, reduced exercise tolerance and progressive congestion may develop over months until an apparently idiopathic cardiomyopathy becomes evident.

Systemic manifestations guide the etiology: arthritis, photosensitivity, ulcers and nephropathy in lupus; Raynaud phenomenon, skin thickening and dysmotility in systemic sclerosis; proximal weakness, rash and dysphagia in myopathies; asthma, sinusitis, neuropathy and eosinophilia in EGPA. Their absence does not exclude an autoimmune process confined to the heart.

Arrhythmia may be the first manifestation even with preserved function; ectopy, ventricular tachycardia, atrial fibrillation and conduction disorders reflect edema, necrosis and scar. Syncope in the presence of autoimmune disease is not automatically attributed to dysautonomia or anemia before an electrical event has been excluded.

Pericarditis frequently coexists in some connective tissue diseases and causes positional pain, friction rub and effusion. In the setting of pericarditis, elevated troponin indicates associated myocardial involvement, whereas new left ventricular dysfunction identifies perimyocarditis and its absence identifies myopericarditis; tamponade and myocarditis may contribute simultaneously to hypotension and require different interventions.

Ischemia and myocarditis have overlapping symptoms, while antiphospholipid antibodies, vasculitis, thrombosis and accelerated atherosclerosis increase coronary probability in autoimmune diseases. A nonischemic CMR pattern is helpful, but coronary assessment remains necessary when age, ECG and biomarker dynamics require it.

Chronic progression manifests with dyspnea, orthopnea, edema, exercise intolerance and arrhythmias. Systemic and cardiac activity may be discordant: a clinically quiescent connective tissue disease does not exclude myocardial inflammation, whereas an articular flare does not prove that heart failure is autoimmune; for this reason, organs are assessed with their own metrics and an independent chronology.

Pregnancy and the puerperium modify immunity and hemodynamics and broaden the differential diagnosis to include peripartum cardiomyopathy. Some immunosuppressive therapies are contraindicated or require planning; preconception counseling reduces the risk of abrupt discontinuations and uncontrolled systemic activity.

In children, myocarditis may accompany rheumatologic or autoinflammatory diseases or post-infectious syndromes. Tachycardia, abdominal pain and reduced feeding may precede explicit cardiac signs; dosing, imaging and support require pediatric centers with joint expertise.

Right-sided involvement may result from myocarditis, pulmonary hypertension, embolism or interstitial lung disease; jugular venous distention and edema do not identify the mechanism. Echocardiography, chest imaging and hemodynamics are integrated because increasing immunosuppression does not correct fibrotic pulmonary hypertension and diuretics alone do not treat active vasculitis.

Fever during autoimmune activity always raises the issue of infection; corticosteroids may attenuate some clinical signs of infection, while a flare may raise C-reactive protein and procalcitonin to varying degrees. Microbiologic samples, imaging and the trajectory precede escalation when stability permits; in shock, antimicrobial and immunologic treatment may begin in parallel after sampling.

Investigations and Diagnosis

ECG, high-sensitivity troponin, natriuretic peptides, echocardiography and rhythm monitoring define the presence and severity of cardiac involvement even when inflammatory markers are normal; complete blood count, renal and hepatic function, urinalysis, complement and muscle tests reconstruct systemic activity and treatment safety.

CMR searches for edema and nonischemic injury using mapping, T2 and late gadolinium enhancement; distribution may suggest a mechanism but does not identify autoimmunity. A negative CMR does not exclude focal or chronic disease, especially if performed late or after corticosteroids.

The immunologic panel is guided by the clinical picture because ANA, anti-dsDNA, ENA, complement, ANCA, myositis-specific antibodies and antiphospholipid antibodies answer different questions. Ordering them without a pre-test probability increases false positives and may transform a coincidence into a causal diagnosis.

Endomyocardial biopsy is particularly useful in shock, dangerous arrhythmias or conduction block, lack of response and selected chronic cardiomyopathy before immunosuppression. Histology and immunohistochemistry quantify infiltrate and necrosis; molecular viral testing should be performed in an expert laboratory with contamination and quality controls.

The definition virus-negative does not mean “no virus is possible”; it depends on the panel, sample, sensitivity and focal distribution. A positive PCR likewise requires interpretation of viral load, replicative activity and localization. The decision integrates biologic probability and does not treat the result as an absolute switch.

Biopsy may identify histologic subtypes that immediately change therapy: giant cells, eosinophils, granulomas or vasculitis. Giant-cell myocarditis is not managed like a common lymphocytic form; review by a cardiovascular pathologist reduces errors in small samples.

Coronary angiography or coronary CT, PET, pulmonary imaging and biopsy of other organs are selected according to the differential diagnosis; PET may reveal activity but does not distinguish autoimmunity, infection and sarcoidosis without context. An accessible extracardiac site may clarify vasculitis or systemic disease, although it does not always replace cardiac biopsy.

Genetic testing is considered in family history, recurrences, conduction disorders, arrhythmias or failure to recover. The presence of a pathogenic variant changes counseling and family surveillance but does not negate a concomitant inflammatory episode, making joint interpretation of phenotype and genotype necessary.

Histology must be correlated with timing because a sample obtained after corticosteroid pulses may show few lymphocytes despite genuine disease, whereas a late biopsy may document only fibrosis. Immunohistochemistry increases sensitivity compared with traditional morphologic criteria, but a low cell density does not prove that inflammation is the main driver of dysfunction.

PET may help in focal activity or suspected sarcoidosis but does not automatically distinguish organ-specific autoimmunity; physiologic suppression of myocardial glucose uptake and steroid therapy influence the result. The test is requested when distribution or an extracardiac site may modify biopsy strategy and not as a universal substitute for CMR.

Treatment and Prognosis

Treatment of forms associated with systemic disease follows the involved organs, severity and disease-specific guidelines; high-dose corticosteroids are often used in severe acute presentations, followed by steroid-sparing immunosuppressants for control and maintenance. The choice among cyclophosphamide, mycophenolate, azathioprine, rituximab or other agents depends on the diagnosis and not merely on the presence of troponin elevation.

In chronic virus-negative lymphocytic inflammatory cardiomyopathy, the TIMIC study evaluated prednisone and azathioprine in biopsy-proven patients symptomatic for more than six months and unresponsive to conventional therapy. The observed benefit does not justify treating an unbiopsied acute myocarditis, a virus-positive form or a cardiomyopathy without inflammation in the same way.

Long-term follow-up of TIMIC supports persistence of benefit in the selected population, but the evidence comes from a single center. Before applying the regimen, biopsy quality, infectious exclusion, adherence to heart-failure therapy and the ability to monitor toxicity are verified, keeping the decision within specialist assessment.

Giant-cell myocarditis, sarcoidosis, eosinophilic myocarditis and vasculitides require their own regimens; a generic label of autoimmunity should not flatten prognostic differences. In refractory cases, diagnostic review precedes the addition of immunosuppression, looking for infection, undertreatment, irreversible fibrosis or a genetic mechanism.

Heart-failure therapy is optimized according to function and tolerance, with diuretics for congestion and devices for established indications. Arrhythmias and conduction block are monitored and treated independently of systemic activity; intense exercise is suspended during the active phase and resumed after clinical and electrical reassessment.

Infection prevention includes screening before immunosuppression, compatible vaccinations, opportunistic prophylaxis and education about symptoms. Fever or new infiltrates during therapy are not interpreted as an autoimmune flare without cultures and imaging; the balance between immune control and antimicrobial defense changes over time.

Prognosis depends on histologic subtype, function, right ventricular involvement, arrhythmias, late gadolinium enhancement and speed of response; troponin normalization may precede structural recovery. Conversely, extensive fibrosis may maintain risk despite complete immunologic remission.

Integrated monitoring follows cardiac and systemic activity on different schedules; ECG, Holter monitoring, echocardiography, CMR and biomarkers are repeated when they can modify therapy. Immunosuppression is reduced gradually, and an isolated rise in one marker does not automatically trigger a new induction course.

In vasculitis with organ involvement, induction aims to stop necrosis and ischemia rapidly, while maintenance prevents recurrence with less toxicity. Cardiac response may be slower than the hematologic response; reducing a regimen solely because ANCA or eosinophils normalize may be premature if troponin, rhythm or imaging remain active.

Intravenous immunoglobulins have a role in some immunologic and pediatric conditions but are not a universal therapy for adult myocarditis. Plasma exchange, rituximab and cyclophosphamide target specific mechanisms and organs; the lack of large cardiac trials does not justify interchangeability among regimens established for different diseases.

Complications

The fulminant form may require ventilation, vasoactive agents and mechanical support; immunosuppression acts on the causal process but does not replace perfusion. The possibility of recovery is high in some forms treated early and justifies rapid referral to centers with advanced support.

Ventricular arrhythmias and conduction block may persist after remission; scar, more than systemic activity, determines part of the late risk. Devices and ablation are evaluated according to history, function and substrate, avoiding both premature implantation during a reversible phase and unprotected discharge.

Chronic dilated cardiomyopathy is the result of inflammation, necrosis and remodeling. When tissue is predominantly fibrotic, increasing immunosuppression offers little benefit and substantial toxicity; neurohormonal therapy, rehabilitation and advanced heart-failure assessment become central.

Opportunistic infections include reactivation of tuberculosis, hepatitis, herpesviruses, pneumocystosis and fungal infections; the profile depends on the regimen. Subtle symptoms may precede severe disease. Prophylaxis and early diagnosis are part of myocarditis treatment, not separate administrative issues.

Hematologic, hepatic, renal, gonadal and oncologic toxicity of immunosuppressants limits duration and combinations. Fertility and pregnancy are discussed before cyclophosphamide or teratogenic drugs when urgency permits; the most powerful option is not always the one with the best benefit-risk ratio.

A recurrence may follow tapering, infection or pregnancy, but must again be differentiated from ischemia and toxicity. The alert plan specifies which symptoms and biomarkers require reassessment; self-managed “as-needed” corticosteroid therapy exposes patients to diagnostic delay and infections.

Systemic autoimmune disease may continue to injure the lungs, kidneys, nerves and vessels even after cardiac recovery. Overall prognosis depends on multiorgan control; coordinated follow-up prevents normalization of the echocardiogram from prematurely ending necessary surveillance.

Heart transplantation remains an option in selected end-stage cardiomyopathy, but autoimmune activity, extracardiac injury and recurrence risk are assessed before listing. Post-transplant immunosuppression may control some forms while promoting infections or neoplasms; the pathway should begin before cachexia and irreversible dysfunction of other organs develop.

Relatives of a patient with a dilated, arrhythmic or recurrent phenotype may need ECG and echocardiography even when the episode has been defined as autoimmune. Genetic predisposition does not exclude immunologic benefit in the proband, but adds a separate hereditary risk; counseling prevents every future family symptom from being attributed to contagion or acquired autoimmunity.

Restrictive physiology may emerge when inflammation, thrombi and fibrosis involve the endomyocardium; at this stage, right-sided congestion, dilated atria and valvular regurgitation may dominate despite nondilated ventricles. The search for residual activity determines whether immunotherapy should be added to structural management, avoiding treatment of mature scar as though it were reversible edema.

Pregnancy is planned during remission, with compatible medications and stable function; immunologic changes in the puerperium may reactivate disease, while common pregnancy symptoms may mask heart failure. A shared plan defines follow-up, analgesia, mode of delivery and postpartum management without imposing cesarean delivery solely because of the history.

Quality of life may remain reduced because of fatigue, pain, dysautonomia, myopathy and fear of recurrence even with normal biomarkers. These symptoms deserve assessment and are not automatically attributed to active inflammation; rehabilitation, sleep, mental health and control of systemic disease complete an outcome that imaging alone does not describe.